AZNAstraZenecaRunning, no new patients
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
Hepatocellular Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 94 (planned)
- Started
- Dec 14, 2023
- Main results expected
- Dec 13, 2027
- Fully finished
- Dec 13, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
1. Incidence of participants with dose-limiting toxicities (DLTs), adverse events (AEs), including adverse events of special interest (AESI) and serious adverse events (SAEs). Determination of the recommended dose of AZD5851 for expansion phase
Measured over: Through study completion, an average of 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06084884 · record last updated 2026-08-19 · checked 2026-11-09 15:47 UTC